Knowledge graph · Trial
Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)
ACTIVE NOT RECRUITING
- Identifier
- CI-TRIAL-00115007
- Entity page
- /trial/NCT03698994 ↗
- Edges
- 34
- Neighbours
- 18 cancers
- Drawn
- 18 of 18 neighbours (cap 60); table lists every fetched edge
Accepted: cancer:<slug>, gene:<symbol>, variant:<slug>, drug:<slug>, trial:<NCT id>, or a bare CI id. Find slugs with search.
Most connectedLung Non-Small Cell Carcinoma 3,149Malignant Colorectal Neoplasm 1,866ABL1 298EGFR 276Imatinib 450Dasatinib 321
Neighbourhood
Radial view
Focus at the centre; neighbours grouped by entity type. Click a node to re-centre the graph on it; ↗ opens the entity page. Hover a spoke for relationship, evidence level, cancer context and source.
Edges
Every edge, grouped by relationship
Source-native edges first (aggregated per neighbour, direction, evidence level and source), then derived registry links. Up to 15 per relationship (10 trials); “show all” raises one group to 200.
| Relationship | Neighbour | Direction | Evidence level | Cancer context | Support | Claim | Source | Expand |
|---|---|---|---|---|---|---|---|---|
| Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial) condition of …CONDITION_OFderived34 of 34show fewer | ||||||||
| ← condition of | Ependymal Tumor registry condition “Recurrent Ependymal Tumor” mapped CURATED_BROADER | — | — | Ependymal Tumor | 1 | Observed | clinicaltrials | graph → |
| ← condition of | Ependymoma registry condition “Refractory Ependymoma” mapped CURATED_BROADER | |||||||